Top

Angiogenesis

Published in:

Open Access 01-11-2020 | Arteriovenous Malformation | Brief Communication

Arterial endoglin does not protect against arteriovenous malformations

Authors: Esha Singh, Rachael E. Redgrave, Helen M. Phillips, Helen M. Arthur

Published in: Angiogenesis | Issue 4/2020

Abstract

Introduction

Endoglin (ENG) forms a receptor complex with ALK1 in endothelial cells (ECs) to promote BMP9/10 signalling. Loss of function mutations in either ENG or ALK1 genes lead to the inherited vascular disorder hereditary haemorrhagic telangiectasia (HHT), characterised by arteriovenous malformations (AVMs). However, the vessel-specific role of ENG and ALK1 proteins in protecting against AVMs is unclear. For example, AVMs have been described to initiate in arterioles, whereas ENG is predominantly expressed in venous ECs. To investigate whether ENG has any arterial involvement in protecting against AVM formation, we specifically depleted the Eng gene in venous and capillary endothelium whilst maintaining arterial expression, and investigated how this affected the incidence and location of AVMs in comparison with pan-endothelial Eng knockdown.

Methods

Using the mouse neonatal retinal model of angiogenesis, we first established the earliest time point at which Apj-Cre-ERT2 activity was present in venous and capillary ECs but absent from arterial ECs. We then compared the incidence of AVMs following pan-endothelial or venous/capillary-specific ENG knockout.

Results

Activation of Apj-Cre-ERT2 with tamoxifen from postnatal day (P) 5 ensured preservation of arterial ENG protein expression. Specific loss of ENG expression in ECs of veins and capillaries led to retinal AVMs at a similar frequency to pan-endothelial loss of ENG. AVMs occurred in the proximal as well as the distal part of the retina consistent with a defect in vascular remodelling during maturation of the vasculature.

Conclusion

Expression of ENG is not required in arterial ECs to protect against AVM formation.

Available only for authorised users

Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R, Grinberg AV (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286(34):30034–30046CrossRef

Saito T, Bokhove M, Croci R, Zamora-Caballero S, Han L, Letarte M, de Sanctis D, Jovine L (2017) Structural basis of the human endoglin-BMP9 interaction: insights into BMP signaling and HHT1. Cell Rep 19(9):1917–1928. https://doi.org/10.1016/j.celrep.2017.05.011CrossRefPubMedPubMedCentral

Lawera A, Tong Z, Thorikay M, Redgrave RE, Cai J, van Dinther M, Morrell NW, Afink GB, Charnock-Jones DS, Arthur HM, Ten Dijke P, Li W (2019) Role of soluble endoglin in BMP9 signaling. Proc Natl Acad Sci USA 116(36):17800–17808. https://doi.org/10.1073/pnas.1816661116CrossRefPubMed

Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23(20):4018–4028. https://doi.org/10.1038/sj.emboj.7600386CrossRefPubMedPubMedCentral

Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24(6):203–219CrossRef

Snellings D, Gallione C, Clark D, Vozoris N, Faughnan M, Marchuk D (2019) Somatic mutations in vascular malformations of hereditary hemorrhagic telangiectasia result in biallelic loss of ENG or ACVRL1. bioRxiv:731588

Tual-Chalot S, Oh SP, Arthur HM (2015) Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges. Front Genet 6:25. https://doi.org/10.3389/fgene.2015.00025CrossRefPubMedPubMedCentral

Torsney E, Charlton R, Diamond AG, Burn J, Soames JV, Arthur HM (2003) Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 107(12):1653–1657. https://doi.org/10.1161/01.CIR.0000058170.92267.00CrossRefPubMed

Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA (2003) A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12(5):473–482. https://doi.org/10.1093/hmg/ddg050CrossRefPubMed

10.

Seki T, Yun J, Oh SP (2003) Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 93(7):682–689CrossRef

11.

Urness LD, Sorensen LK, Li DY (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26(3):328–331. https://doi.org/10.1038/81634CrossRefPubMed

12.

Tual-Chalot S, Mahmoud M, Allinson KR, Redgrave RE, Zhai Z, Oh SP, Fruttiger M, Arthur HM (2014) Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression. PLoS ONE 9(6):e98646. https://doi.org/10.1371/journal.pone.0098646CrossRefPubMedPubMedCentral

13.

Jin Y, Muhl L, Burmakin M, Wang Y, Duchez AC, Betsholtz C, Arthur HM, Jakobsson L (2017) Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling. Nat Cell Biol 19(6):639–652. https://doi.org/10.1038/ncb3534CrossRefPubMedPubMedCentral

14.

Moya IM, Umans L, Maas E, Pereira PN, Beets K, Francis A, Sents W, Robertson EJ, Mummery CL, Huylebroeck D, Zwijsen A (2012) Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell 22(3):501–514. https://doi.org/10.1016/j.devcel.2012.01.007CrossRefPubMedPubMedCentral

15.

Larrivee B, Prahst C, Gordon E, del Toro R, Mathivet T, Duarte A, Simons M, Eichmann A (2012) ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell 22(3):489–500. https://doi.org/10.1016/j.devcel.2012.02.005CrossRefPubMedPubMedCentral

16.

Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA, Weinstein BM (2001) Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128(19):3675–3683PubMed

17.

Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T (2004) Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 18(20):2469–2473. https://doi.org/10.1101/gad.1239204CrossRefPubMedPubMedCentral

18.

Allinson KR, Carvalho RL, van den Brink S, Mummery CL, Arthur HM (2007) Generation of a floxed allele of the mouse Endoglin gene. Genesis 45(6):391–395CrossRef

19.

Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T, Nobes CD, Adams RH (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465(7297):483–486. https://doi.org/10.1038/nature09002CrossRef

20.

Chen HI, Sharma B, Akerberg BN, Numi HJ, Kivela R, Saharinen P, Aghajanian H, McKay AS, Bogard PE, Chang AH, Jacobs AH, Epstein JA, Stankunas K, Alitalo K, Red-Horse K (2014) The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis. Development 141(23):4500–4512. https://doi.org/10.1242/dev.113639CrossRefPubMedPubMedCentral

21.

Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L (2007) A global double-fluorescent Cre reporter mouse. Genesis 45(9):593–605. https://doi.org/10.1002/dvg.20335CrossRefPubMed

22.

Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, Fruttiger M, Arthur HM (2010) Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106(8):1425–1433CrossRef

23.

Tual-Chalot S, Allinson KR, Fruttiger M, Arthur HM (2013) Whole mount immunofluorescent staining of the neonatal mouse retina to investigate angiogenesis in vivo. J Vis Exp 77:e50546. https://doi.org/10.3791/50546CrossRef

24.

Crist AM, Young C, Meadows SM (2017) Characterization of arteriovenous identity in the developing neonate mouse retina. Gene Expr Patterns 23–24:22–31. https://doi.org/10.1016/j.gep.2017.01.002CrossRefPubMed

25.

Xu C, Hasan SS, Schmidt I, Rocha SF, Pitulescu ME, Bussmann J, Meyen D, Raz E, Adams RH, Siekmann AF (2014) Arteries are formed by vein-derived endothelial tip cells. Nat Commun 5:5758. https://doi.org/10.1038/ncomms6758CrossRefPubMedPubMedCentral

26.

Red-Horse K, Siekmann AF (2019) Veins and arteries build hierarchical branching patterns differently: bottom-up versus top-down. Bioessays 41(3):e1800198. https://doi.org/10.1002/bies.201800198CrossRefPubMedPubMedCentral

27.

Fruttiger M (2007) Development of the retinal vasculature. Angiogenesis 10(2):77–88CrossRef

28.

Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, Seaward MR, Willett KL, Aderman CM, Guerin KI, Hua J, Lofqvist C, Hellstrom A, Smith LE (2010) The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 51(6):2813–2826. https://doi.org/10.1167/iovs.10-5176CrossRefPubMedPubMedCentral

29.

Tual-Chalot S, Garcia-Collado M, Redgrave RE, Singh E, Davison B, Park C, Lin H, Luli S, Jin Y, Wang Y, Lawrie A, Jakobsson L, Arthur HM (2020) Loss of endothelial endoglin promotes high-output heart failure through peripheral arteriovenous shunting driven by VEGF signaling. Circ Res 126(2):243–257. https://doi.org/10.1161/CIRCRESAHA.119.315974CrossRefPubMed

30.

Rochon ER, Wright DS, Schubert MM, Roman BL (2015) Context-specific interactions between Notch and ALK1 cannot explain ALK1-associated arteriovenous malformations. Cardiovasc Res 107(1):143–152. https://doi.org/10.1093/cvr/cvv148CrossRefPubMedPubMedCentral

31.

Upton PD, Davies RJ, Trembath RC, Morrell NW (2009) Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 284(23):15794–15804. https://doi.org/10.1074/jbc.M109.002881CrossRefPubMedPubMedCentral

32.

Corti P, Young S, Chen CY, Patrick MJ, Rochon ER, Pekkan K, Roman BL (2011) Interaction between alk1 and blood flow in the development of arteriovenous malformations. Development 138(8):1573–1582. https://doi.org/10.1242/dev.060467CrossRefPubMedPubMedCentral

33.

Garrido-Martin EM, Blanco FJ, Roque M, Novensa L, Tarocchi M, Lang UE, Suzuki T, Friedman SL, Botella LM, Bernabeu C (2013) Vascular injury triggers Kruppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene. Circ Res 112(1):113–127. https://doi.org/10.1161/CIRCRESAHA.112.275586CrossRefPubMed

Title: Arterial endoglin does not protect against arteriovenous malformations
Authors: Esha Singh
Rachael E. Redgrave
Helen M. Phillips
Helen M. Arthur
Publication date: 01-11-2020
Publisher: Springer Netherlands
Keywords: Arteriovenous Malformation
Tamoxifen
Published in: Angiogenesis / Issue 4/2020
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-020-09731-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients

Excess centrosomes disrupt vascular lumenization and endothelial cell adherens junctions

Heterogeneity and chimerism of endothelial cells revealed by single-cell transcriptome in orthotopic liver tumors

Pleiotrophin selectively binds to vascular endothelial growth factor receptor 2 and inhibits or stimulates cell migration depending on ανβ3 integrin expression

Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials